U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) <https://www.nichd.nih.gov/>
For Immediate Release: Tuesday, April 2, 2019
CONTACT: Robert Bock or Meredith Daly, 301-496-5134, <e-mail: nichdpress@xxxxxxxxxxxx>
MEDIA AVAILABILITY
GOUT TREATMENT MAY HELP PREVENT OBESITY-RELATED TYPE 2 DIABETES, SUGGESTS SMALL NIH STUDY
WHAT:
The drug colchicine < https://medlineplus.gov/druginfo/meds/a682711.html>, used to treat the arthritic condition gout < https://medlineplus.gov/gout.html>, could potentially reduce complications accompanying metabolic syndrome < https://medlineplus.gov/metabolicsyndrome.html>, a combination of high blood pressure, high blood sugar and other conditions that increase the risk of heart disease and type 2 diabetes, according to researchers at the National Institutes of Health. Their study appears in Diabetes, Endocrinology, and Metabolism.
Previous studies have indicated that the system-wide inflammation that occurs in obesity plays a role in the development of type 2 diabetes. In the current study, researchers led by Jack A. Yanovski, M.D., Ph.D., of NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) randomly assigned 21 study participants to received colchicine twice a day for 3 months, while 19 participants received a placebo. Colchicine suppresses a multi-protein complex called NLRP3, which triggers the inflammation seen in obesity.
Researchers looked at several measures that reflect how well insulin works in the body to clear sugar from the blood (insulin resistance). There was no difference between the two groups in insulin resistance determined by one measure of insulin use (the frequently sampled, insulin-modified intravenous glucose tolerance test). However, the colchicine group showed improvement on the Homeostatic Model Assessment of Insulin Resistance test, which also estimates how much insulin is needed to keep blood sugar at a normal level while fasting. Those in the colchicine group also scored lower on a blood test of C-reactive protein < https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/>and other tests that indicate inflammation. The authors concluded that larger studies are needed to determine if colchicine could prevent the development of type 2 diabetes in people with metabolic syndrome.
The research was also supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.
WHO:
Jack Yanovski, M.D., Ph.D., Chief of the NICHD Section on Growth and Obesity, is available for comment.
ARTICLE:
Demidowich, AP et al. Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. Diabetes, Endocrinology, and Metabolism.2019
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD conducts and supports research in the United States and throughout the world on fetal, infant and child development; maternal, child and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit NICHD's website < https://www.nichd.nih.gov/>.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
This NIH News Release is available online at:
<https://www.nih.gov/news-events/news-releases/gout-treatment-may-help-prevent-obesity-related-type-2-diabetes-suggests-small-nih-study>.
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
